CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maddocks: So let ...
Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...
SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers. Perspective ...
Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback